-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
Usher Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration and prolonged and unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids, and Vitamin A supplementation. The Usher syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Usher syndrome, complete with analysis by stage of...
-
Product Insights
Net Present Value Model: QRX-421a
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model QRX-421a Drug Details QRX-421a is under...
-
Product Insights
Net Present Value Model: Sepofarsen
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sepofarsen Drug Details QR-110 is under...
-
Track & Monitor
Innovation in Pharmaceuticals: Anti-sense nucleotide-based compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Anti-sense nucleotide-based compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – QRX-421a
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry QRX-421a Drug Details QRX-421a is under development for the treatment of Usher syndrome due...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sepofarsen
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sepofarsen Drug Details QR-110 is under development for the treatment of Leber's congenital amaurosis...
-
Product Insights
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber Congenital Amaurosis (LCA) is the most common cause of inherited blindness in childhood. Its symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. The Leber Congenital Amaurosis pipeline market research report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Juvenile Macular Degeneration is mostly found in the form of Stargardt disease. Stargardt's disease can occur with symptoms that include blurry or fuzzy vision, dark, empty spots in the center of vision, and difficulty reading or performing detail work. The Juvenile Macular Degeneration (Stargardt Disease) pipeline market research report provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis...